344 related articles for article (PubMed ID: 23062579)
1. Risk associated with a systematic search of extended-spectrum β-lactamase-producing Enterobacteriaceae.
Prinapori R; Guinaud J; Khalil A; Lecuyer H; Gendrel D; Lortholary O; Nassif X; Viscoli C; Zahar JR
Am J Infect Control; 2013 Mar; 41(3):259-60. PubMed ID: 23062579
[TBL] [Abstract][Full Text] [Related]
2. The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials.
Trivedi M; Patel V; Soman R; Rodriguez C; Singhal T
J Assoc Physicians India; 2012 Aug; 60():28-30. PubMed ID: 23405518
[TBL] [Abstract][Full Text] [Related]
3. Carbapenem-resistant enterobacteriaceae: an emerging problem in children.
Logan LK
Clin Infect Dis; 2012 Sep; 55(6):852-9. PubMed ID: 22700827
[TBL] [Abstract][Full Text] [Related]
4. Clinical features of nosocomial infections by extended-spectrum beta-lactamase-producing Enterobacteriaceae in neonatal intensive care units.
Chiu S; Huang YC; Lien RI; Chou YH; Lin TY
Acta Paediatr; 2005 Nov; 94(11):1644-9. PubMed ID: 16303704
[TBL] [Abstract][Full Text] [Related]
5. Proportion of rectal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in the inpatients of a pediatric tertiary care hospital in Japan.
Minami K; Shoji Y; Kasai M; Ogiso Y; Nakamura T; Kawakami Y; Saito Y; Kuzumoto K; Kubota N; Yumoto K; Ishii K
Jpn J Infect Dis; 2012; 65(6):548-50. PubMed ID: 23183211
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Doi A; Shimada T; Harada S; Iwata K; Kamiya T
Int J Infect Dis; 2013 Mar; 17(3):e159-63. PubMed ID: 23140947
[TBL] [Abstract][Full Text] [Related]
7. Outcome of urinary tract infections caused by extended spectrum β-lactamase-producing Enterobacteriaceae in children.
Tratselas A; Iosifidis E; Ioannidou M; Saoulidis S; Kollios K; Antachopoulos C; Sofianou D; Roilides EJ
Pediatr Infect Dis J; 2011 Aug; 30(8):707-10. PubMed ID: 21248655
[TBL] [Abstract][Full Text] [Related]
8. [Extended-spectrum beta-lactamase producing-enterobacteriaceae].
Mariani-Kurkdjian P; Doit C; Bingen E
Arch Pediatr; 2012 Nov; 19 Suppl 3():S93-6. PubMed ID: 23178141
[TBL] [Abstract][Full Text] [Related]
9. Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) infections: are carbapenem alternatives achievable in daily practice?
Pilmis B; Delory T; Groh M; Weiss E; Emirian A; Lecuyer H; Lesprit P; Zahar JR
Int J Infect Dis; 2015 Oct; 39():62-7. PubMed ID: 26327124
[TBL] [Abstract][Full Text] [Related]
10. Antibiotic therapy for inducible AmpC β-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides?
Harris PN; Ferguson JK
Int J Antimicrob Agents; 2012 Oct; 40(4):297-305. PubMed ID: 22824371
[TBL] [Abstract][Full Text] [Related]
11. Treatment of pyelonephritis caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in children.
Katsuta T; Shoji K; Watanabe Y; Saitoh A
Pediatr Infect Dis J; 2013 Apr; 32(4):417-9. PubMed ID: 23274920
[TBL] [Abstract][Full Text] [Related]
12. Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing enterobacteriaceae.
Kim SA; Altshuler J; Paris D; Fedorenko M
Int J Antimicrob Agents; 2018 Jan; 51(1):155-158. PubMed ID: 28943367
[TBL] [Abstract][Full Text] [Related]
13. Extended-spectrum β-lactamase-producing Enterobacteriaceae, national study of antimicrobial treatment for pediatric urinary tract infection.
Lagree M; Bontemps S; Dessein R; Angoulvant F; Madhi F; Martinot A; Cohen R; Dubos F;
Med Mal Infect; 2018 May; 48(3):193-201. PubMed ID: 29449049
[TBL] [Abstract][Full Text] [Related]
14. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis.
Vardakas KZ; Tansarli GS; Rafailidis PI; Falagas ME
J Antimicrob Chemother; 2012 Dec; 67(12):2793-803. PubMed ID: 22915465
[TBL] [Abstract][Full Text] [Related]
15. New Delhi Metallo-beta lactamase (NDM-1) in Enterobacteriaceae: treatment options with carbapenems compromised.
Deshpande P; Rodrigues C; Shetty A; Kapadia F; Hedge A; Soman R
J Assoc Physicians India; 2010 Mar; 58():147-9. PubMed ID: 20848811
[TBL] [Abstract][Full Text] [Related]
16. Associated factors and outcomes for OXA-232 Carbapenem-resistant Enterobacteriaceae infections in a tertiary care centre in Mexico City: A case-control-control study.
Torres-González P; Ortiz-Brizuela E; Cervera-Hernandez ME; Bobadilla-Del Valle M; Martínez-Gamboa A; Sifuentes-Osornio J; Ponce-de-Leon A
Diagn Microbiol Infect Dis; 2016 Oct; 86(2):243-8. PubMed ID: 27519297
[TBL] [Abstract][Full Text] [Related]
17. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.
Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
Clin Infect Dis; 2013 Feb; 56(4):488-95. PubMed ID: 23090931
[TBL] [Abstract][Full Text] [Related]
18. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella.
Huang SS; Lee MH; Leu HS
J Microbiol Immunol Infect; 2006 Dec; 39(6):496-502. PubMed ID: 17164953
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Asakura T; Ikeda M; Nakamura A; Kodera S
Int J Infect Dis; 2014 Dec; 29():91-5. PubMed ID: 25461239
[TBL] [Abstract][Full Text] [Related]
20. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?
Harris PN; Tambyah PA; Paterson DL
Lancet Infect Dis; 2015 Apr; 15(4):475-85. PubMed ID: 25716293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
